ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

• Published in: International journal of colorectal disease Vol. 24; no. 9; pp. 1059 - 1068
• Main Authors: Baiocchi, Glauco, Lopes, Ademar, Coudry, Renata A, Rossi, Benedito M, Soares, Fernando A, Aguiar, Samuel, Guimarães, Gustavo C, Ferreira, Fabio O, Nakagawa, Wilson T
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01-09-2009; Springer-Verlag; Springer; Springer Nature B.V
• Subjects: Aged; Biological and medical sciences; Colorectal Neoplasms - pathology; Colorectal Neoplasms - surgery; Cytoplasm - chemistry; Digestive System Surgical Procedures; Female; Gastroenterology; Gastroenterology. Liver. Pancreas. Abdomen; Hepatology; Humans; Immunohistochemistry; Internal Medicine; Lymphatic Vessels - pathology; Male; Medical sciences; Medicine; Medicine & Public Health; Membrane Proteins - analysis; Middle Aged; Original Article; Proctology; Prognosis; Receptor, Epidermal Growth Factor - analysis; Receptor, ErbB-2 - analysis; Receptor, ErbB-3 - analysis; Receptor, ErbB-4; Recurrence; Risk; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Surgery; Tumors; Immunohistochemistry; Rectal neoplasm; Prognosis; Colonic neoplasm; ErbB; Microarray analysis; Human; Relapse; Rectal disease; Family study; Colorectal cancer; Malignant tumor; Colonic disease; Anatomic pathology; Treatment; Surgery; Risk factor; Gastroenterology; Rectum; Digestive diseases; Intestinal disease; Colon; Cancer
• ISSN: 0179-1958; 1432-1262
• DOI: 10.1007/s00384-009-0702-6

Purpose Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment. Methods We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique. Results The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis. Conclusions The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.